Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.

Spine

Volumn 38, Issue 22 Suppl 1, 2013, Pages

  Fehlings, Michael G ^a   Wilson, Jefferson R ^b   Karadimas, Spyridon K ^b   Arnold, Paul M ^b   Kopjar, Branko ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; RILUZOLE;

CERVICAL SPINE; DRUG EFFECT; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPINAL CORD DISEASE; SPONDYLOSIS; TREATMENT OUTCOME;

CERVICAL VERTEBRAE; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RILUZOLE; SPINAL CORD DISEASES; SPONDYLOSIS; TREATMENT OUTCOME;

EID: 85027937842     PISSN: None     EISSN: 15281159     Source Type: Journal    
DOI: None     Document Type: Review

References (0)